Prescribing exercise for diabetes prevention
| ISRCTN | ISRCTN50086114 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN50086114 |
| Protocol serial number | CCT-83029 |
| Sponsor | Aging, Rehabilitation & Geriatric Care Research Centre (Canada) |
| Funder | Canadian Institutes of Health Research (CIHR) (Canada) - http://www.cihr-irsc.gc.ca - CVC Diabetes Team (ref: CCT-83029) |
- Submission date
- 30/07/2009
- Registration date
- 11/02/2010
- Last edited
- 11/02/2010
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Nutritional, Metabolic, Endocrine
Plain English summary of protocol
Not provided at time of registration
Contact information
Scientific
Aging, Rehabilitation & Geriatric Care Research Centre
Parkwood Hospital, B-3002b
801 Commissioners Road East
London
N6C 5J1
Canada
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Multicentre prospective randomised controlled trial |
| Secondary study design | Randomised controlled trial |
| Study type | Participant information sheet |
| Scientific title | A multicentre, prospective, randomised study to determine the effects of an exercise managed intervention (ARTEMIStudy) |
| Study acronym | ARTEMIS |
| Study objectives | Primary objective: To compare the reduction in mean systolic blood pressure (SBP) within the first 4 hours of awakening using an automated home blood pressure device, in patients treated for 12 weeks with a combined aerobic and resistance exercise program versus usual care. Secondary objectives: 1. To compare the reduction in mean SBP and diastolic blood pressure (DBP) as recorded by ambulatory home BP (A&D Medical Blood Pressure Monitor with Bluetooth®) 2. To compare the change in fasting glucose levels (LifeScan OneTouch Ultra II Blood Glucose Monitor + Polymap Bluetooth® Adaptor for the OneTouch Ultra II), and HbA1c levels 3. To compare the change in triglyceride, high density lipoprotein cholesterol (HDLc) and low density lipoprotein cholesterol (LDLc) levels 4. To compare the reduction in mean SBP and DBP, as recorded by clinic BP using BpTRU™ 5. To compare the reduction in waist circumference and weight 6. To compare the improvement in mean steps per day using an Omron® pedometer 7. To compare the change in resting heart rate and heart rate variability over 24 hours 8. To compare the change in stage of change for physical activity (Prochaska and DiClemente's "Stage of Change" model) 9. To compare the change in predicted maximal oxygen consumption (VO2max) using the STEP™ test 10. To compare the change in quality of life (using 36-item short form health survey [SF-36], version 2) 11. To compare the change in vascular geometry and elastic properties of the carotid, aorta and femoral arteries 12. To compare the change in muscle sympathetic nerve activity discharge patterns and how this relates to peripheral (i.e., forearm) and systemic vascular resistance 13. To compare the change in C-reactive protein (CRP), insulin, catecholamines, vasopressin, plasma renin activity, angiotensin II, aldosterone, oestrogen, progesterone, cortisol, creatinine, microalbumin, homocysteine, heat shock proteins, adiponectin, and leptin 14. To compare the change in 3D ultrasound and cardiac function (echocardiography; including systolic function, diastolic function, ejection fraction, left ventricular wall dimensions and volume and stroke volume) 15. To compare the change in self efficacy (measured by diabetes and physical activity scales) Phase 1 and 2 exercise intervention groups will then be compared at all timepoints (weeks 12, 24, 52). Because exercise interventions have appreciable attrition rates of up to 50% at six months; we will assess both intervention groups again at 6 months post study to determine decay effects. Hypotheses: Null hypotheses: 1. Improved exercise behaviours in either phase 1 or 2 will not enhance primary, secondary or tertiary outcomes 2. There will be more change of primary, secondary and tertiary outcomes in institutional versus community settings (phase 1 versus 2) Alternative hypotheses: 1. Improved exercise behaviours in either phase 1 or 2 will enhance primary, secondary or tertiary outcomes 2. There will be equivalent change in primary, secondary and tertiary outcomes in phase 1 and 2 settings 3. The model of cardiovascular disease (CVD) risk factor diminution in metabolic syndrome described herein will be effectively deployed using a translational research approach using allied health care provider prescription |
| Ethics approval(s) | The University of Western Ontario Research Ethics Board for Health Sciences Involving Human Subjects (HSREB) approved on the 10th March 2009 (ref: 15828) |
| Health condition(s) or problem(s) studied | Metabolic syndrome; cardiovascular complications of type 2 diabetes |
| Intervention | Patients with metabolic syndrome from an urban community (London, Ontario) will be randomly assigned to either the combined aerobic-resistance exercise intervention or exercise control groups in an institutional-academic research setting. At another study site (rural Ontario), participants representing each group will be randomly assigned to a combined aerobic-resistance exercise intervention or exercise control groups in a home-based setting where all clinical data and intervention will be matched to the institutional site but delivered using wireless-enabled technology. The study will continue for one year for both interventional settings (rural and institutional). Follow up will be for one year. |
| Intervention type | Other |
| Primary outcome measure(s) |
1. Clinical blood pressure, recorded using a programmable automated device (BP-TRU™ 100 model, Vancouver, BC) |
| Key secondary outcome measure(s) |
1. 3D ultrasound measurement of carotid artery: patients will undergo a 3D ultrasound exam to assess the extent of their carotid atheromatous disease |
| Completion date | 31/12/2012 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | All |
| Target sample size at registration | 720 |
| Key inclusion criteria | 1. Male or female 2. Aged 18 to 70 years 3. Presents with metabolic syndrome as defined by having SBP greater than 130 mmHg and/or DBP greater than 85 mmHg and any two of the following criteria: 3.1. Abdominal obesity (waist circumference greater than 102 cm in males; greater than 88 cm in females) 3.2. Fasting triglycerides greater than 1.695 mmol/L 4. Low HDL cholesterol: males less than 1.04 mmol/L; females less than 1.29 mmol/L 5. Fasting glucose greater than 5.60 mmol/L |
| Key exclusion criteria | Any patient who: 1. Has an in-clinic mean SBP greater than or equal to 180 mmHg and/or DBP greater than or equal to 110 mmHg 2. Has a history of myocardial infarction, angioplasty, coronary artery bypass, or cerebrovascular ischaemia/stroke 3. Has symptomatic congestive heart failure 4. Has atrial flutter 5. Has uncontrolled hypertension 6. Has unstable angina 7. Has unstable pulmonary disease (e.g., asthma or obstructive lung disease) 8. Uses medications known to affect heart rate (e.g., beta-blockers) 9. Has second or third degree heart block 10. Has a history of alcoholism, drug abuse, or other emotional, cognitive or psychiatric problem that is likely to impair compliance to the study 11. Requires the continuation of other medication which might interfere with the objectives of the study 12. Has a pacemaker 13. Has unstable metabolic disease (e.g. uncontrolled thyroid disease) 14. Has orthopaedic or rheumatologic problems that could impair ability to exercise 15. Has a history of allergy to any of the study drugs 16. Started, or changed dose of, a lipid lowering agent(s) within the previous 3 months 17. Is currently enrolled in a clinical research trial |
| Date of first enrolment | 01/08/2009 |
| Date of final enrolment | 31/12/2012 |
Locations
Countries of recruitment
- Canada
Study participating centre
N6C 5J1
Canada
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
| Study website | Study website | 11/11/2025 | 11/11/2025 | No | Yes |